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Objectives
We sought to evaluate whether people living with HIV (PLWH) using effective antiretroviral
therapy (ART) have worse respiratory health status than similar HIV-negative individuals.
Methods
We recruited 197 HIV-positive and 93 HIV-negative adults from HIV and sexual health clinics. They
completed a questionnaire regarding risk factors for respiratory illness. Respiratory health status was
assessed using the St George’s Respiratory Questionnaire (SGRQ) and the Medical Research Council
(MRC) breathlessness scale. Subjects underwent spirometry without bronchodilation.
Results
PLWH had worse respiratory health status: the median SGRQ Total score was 12 [interquartile
range (IQR) 6–25] in HIV-positive subjects vs. 6 (IQR 2–14) in HIV-negative subjects (P < 0.001);
breathlessness was common in the HIV-positive group, where 47% compared with 24% had an
MRC breathlessness score ≥ 2 (P = 0.001). Eighteen (11%) HIV-positive and seven (9%) HIV-
negative participants had airflow obstruction. In multivariable analyses (adjusted for age, gender,
smoking, body mass index and depression), HIV infection remained associated with higher SGRQ
and MRC scores, with an adjusted fold-change in SGRQ Total score of 1.54 [95% confidence
interval (CI) 1.14–2.09; P = 0.005] and adjusted odds ratio of having an MRC score of ≥ 2 of 2.45
(95% CI 1.15–5.20; P = 0.02). Similar findings were obtained when analyses were repeated
including only HIV-positive participants with a viral load < 40 HIV-1 RNA copies/mL.
Conclusions
Despite effective ART, impaired respiratory health appears more common in HIV-positive adults,
and has a significant impact on health-related quality of life.
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Introduction
Antiretroviral therapy (ART) has transformed HIV infec-
tion into a manageable chronic condition [1]. Despite
this, people living with HIV (PLWH) continue to have
higher rates of comorbidities such as cardiovascular [2]
and renal disease [3], as well as some malignancies [4].
There is also evidence that, despite ART, PLWH may have
a higher prevalence of chronic respiratory illness [5]. For
instance, in the large US Veterans Aging Cohort Study,
after adjustment for smoking status and other character-
istics, chronic obstructive pulmonary disease (COPD) was
50–60% more common in PLWH than in HIV-negative
participants [6]. The development of persistent, noncom-
municable respiratory disease such as COPD in HIV-posi-
tive individuals may impact significantly on their quality
of life [7].
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There are, however, limitations to the currently
available data concerning chronic respiratory disease in
HIV-positive people on ART. In particular, most reported
studies have included significant proportions of partici-
pants without virological suppression. Also, results may
be influenced by residual confounding factors such as
tobacco smoking and recreational drug use. Furthermore,
most studies assessing respiratory health in HIV-positive
populations have focused on objective measurements of
lung function (such as spirometry) rather than the subjec-
tive impact of respiratory impairment on health-related
quality of life [5, 8]. This is an important issue, as respi-
ratory symptoms can correlate poorly with objectively
measured lung function [9], yet may have a significant
effect on quality of life. There is a need, therefore, to bet-
ter understand the degree to which PLWH with access to
effective ART have worse respiratory health than HIV-
negative individuals (with similar risk factors), and the
impact of this on their quality of life [10].
The use of validated patient-reported outcome measures
allows the systematic evaluation of the impact of patholo-
gies on health-related quality of life, and enables direct
comparisons to be made between different groups and
populations. These instruments can attempt to quantify
general health status (such as the EuroQoL 5D 5L (EQ5D))
or may be disease or organ specific [e.g. the St George’s
Respiratory Questionnaire (SGRQ)]. In this study, we used
these measures to provide an assessment of overall respi-
ratory health (rather than an assessment specific to one
condition such as COPD) – which we refer to as “respira-
tory health status”.
We sought to evaluate whether respiratory health
status was impaired in a contemporary (on ART) HIV-
infected population and to test the hypothesis that HIV-
positive adults have worse respiratory health than
HIV-negative people with similar risk factors; to assess
whether impaired respiratory health correlated with spiro-
metric impairment in this population, and to explore the
effect of potential confounding factors such as smoking,
recreational drug use, and physical and mental comor-
bidities. In addition, for those with HIV infection, we
describe the relationship between HIV-related factors
such as blood CD4 count, HIV load and duration of HIV
infection and respiratory health status.
Methods
Study population
We conducted a cross-sectional observational study in the
HIV ambulatory care service and sexual health clinics (at
Royal Free and Barnet Hospital sites) of the Royal Free
London NHS Trust, London, UK from February to July
2015. Consecutive clinic patients were invited to take part
in the study when they attended routine care appointments.
Subjects provided written informed consent. London sexual
health clinics were chosen as the site for recruitment of
HIV-negative participants as this population was antici-
pated to have similar lifestyle characteristics, including
smoking behaviours, to the HIV clinic population. As ser-
vice users in the sexual health clinics were significantly
younger than those attending clinics for HIV care, recruit-
ment in sexual health clinics was restricted to those over
the age of 35 years to achieve a sample that approximated
the age of the HIV-positive participants. There were no
exclusion criteria for the HIV-positive group. Ethical
approval was granted by the London – Camden and Isling-
ton Research Ethics Committee (14/LO/1646).
Procedures
Participants completed a questionnaire including items
on risk factors for respiratory illness, smoking and
recreational drug use and health-related quality of life
(using the EQ5D) [11,12,13]. As depression might affect
the experience and expression of respiratory symptoms
(and therefore act as an important confounding factor),
symptoms of depression were evaluated using the
Patient Health Questionnaire – 9 (PHQ-9) (a scale pro-
viding scores of 0–27, where scores of ≥ 10 suggest the
presence of moderate or severe depressive symptoms
[14]). Respiratory health status was measured using (a)
the SGRQ and (b) the Medical Research Council dysp-
noea (breathlessness) scale, a scale with scores from 1 to
5 recording the severity of breathlessness on exertion
[15, 16].
The SGRQ is a patient-reported outcome measure
which quantifies respiratory health using a 50-item self-
completed questionnaire [15]. Responses are translated
onto a scale from 0 to 100 in which higher scores indi-
cate worse respiratory health status, with domains assess-
ing symptoms, activities and impacts as well as a total
score. Although initially developed for use in asthma and
COPD, it is not disease-specific and has been widely used
in other respiratory conditions.
Subjects underwent spirometry without bronchodilation
(Carevision Micro I spirometer, Beckton Dickinson, New
Jersey, USA) and had their height and weight measured.
Normal values for spirometry were calculated using the
Global Lung Function Initiative equations [17]; airflow
obstruction was defined as an Forced Expiratory Volume in
one second (FEV1)/ Forced Vital Capacity (FVC) of < 0.7.
For current and past blood test results, data were obtained
from hospital databases with participant consent. Self-
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reported HIV status was noted and not independently con-
firmed in the sexual health clinic population.
Statistical analysis
Data were recorded and analysed in EXCEL (Microsoft) and
SPSS version 22 (IBM, New York, USA). Univariable com-
parisons between HIV-positive and -negative participants
were undertaken using v2 and Fisher’s exact tests for cate-
gorical variables and unpaired t-tests or Mann–Whitney
U-tests for continuous variables, as appropriate. To adjust
for participant characteristics and to assess the indepen-
dent associations of factors with respiratory measures,
multivariable regression analyses were performed. SGRQ
Total scores were log-transformed to normalize their dis-
tribution for these analyses. Multivariable linear regres-
sion analyses were used to assess factors independently
associated with log-transformed SGRQ Total scores and
estimates were then back-transformed to derive adjusted
fold-changes in SGRQ score for covariates of interest.
Multivariable logistic regression models were used to
assess factors independently associated with having an
MRC dyspnoea score of ≥ 2. For the multivariable analy-
ses, a core set of variables of importance were selected a
priori (age, tobacco smoking, gender and HIV status) and,
following univariable analysis, additional variables found
to be significantly associated at the 5% level with respira-
tory health status were added to the multivariable model.
Results
Study participants
Of 402 individuals invited to participate, 290 (72%)
agreed: 197 HIV positive and 93 HIV negative. Recruit-
ment of HIV-negative individuals was lower as fewer eli-
gible individuals attended these clinics over the study
period – however, the response rate was similar, being
75% among HIV-positive individuals and 73% among
HIV-negative individuals. Demographics and details of
comorbid conditions are listed in Tables 1 and 2.
The median blood CD4 count of HIV-positive
participants was 627 cells/lL [interquartile range (IQR)
456–838 cells/lL]; 171 (94%) of PLWH reported using ART,
with a median duration of treatment of 7 years. Eighty-
nine per cent of all PLWH and 93% of those using ART had
an undetectable plasma HIV load (< 40 HIV-1 RNA copies/
mL) at their last clinic visit. The median nadir CD4 count of
this cohort was 250 cells/lL (IQR 122–365 cells/lL). No
significant differences were found in gender, educational
attainment or being non-UK born between HIV-positive
and -negative participants, but PLWH were more often
ethnically white (72% vs. 60%, respectively; P = 0.001).
HIV-negative participants had a lower median age than
those recruited from the HIV ambulatory care clinic (43 vs.
50 years, respectively; P = 0.05) and were more likely to be
heterosexual (71% vs. 32%, respectively; P < 0.01).
The HIV-positive and -negative groups had similar
reported prevalences of a range of physical comorbidities
(asthma, COPD, diabetes, heart disease and stroke). How-
ever, symptoms of depression were more common in the
HIV-positive group: 39 (20%) of the HIV-positive group
and 13 (14%) of the HIV-negative group had PHQ-9 scores
of ≥ 10, indicating moderate/severe depression (P = 0.64).
Smoking and recreational drug use
Sixty (30%) HIV-positive and 31 (33%) HIV-negative partici-
pants were current smokers; 54 (28%) and 22 (25%), respec-
tively, were ex-smokers (Table 3). In smokers, PLWH reported
more intensive smoking than HIV-negative individuals, with
Table 1 Comparison of demographic characteristics between
HIV-positive and HIV-negative participants
HIV-positive
(n = 197)
HIV-negative
(n = 93) P-value
Gender
Male [n (%)] 158 (80) 64 (71) 0.09*
Age (years) [median (IQR)] 50 (42–55) 43 (38–52) 0.025#
BMI (kg/m2) [mean (SD)] 25.84 (5.04) 25.36 (4.23) 0.4349
Race/ethnicity [n (%)]
White 143 (72) 54 (60) 0.003□
Black 37 (20) 15 (17)
Other 15 (8) 24 (26)
Born in UK [n (%)] 121 (62) 49 (54) 0.24*
Gender/sexuality [n (%)]
MSM 131 (66) 25 (27) < 0.001□
MSW 27 (14) 37 (40)
Female 37 (20) 24 (28)
Not stated 0 5 (5)
Highest educational attainment [n (%)]
None 24 (12) 10 (12) 0.64□
GCSE or equivalent 28 (14) 7 (8)
A level or equivalent 31 (16) 14 (16)
University degree or higher 106 (54) 50 (59)
Other 6 (3) 4 (5)
Employment [n (%)]
Full-time 92 (47) 59 (67) 0.015□
Part-time 22 (11) 11 (12)
Unemployed 25 (13) 5 (6)
Retired 18 (9) 4 (4)
Student 5 (3) 1 (1)
Not working because
of ill health
28 (14) 4 (5)
Other 6 (3) 5 (5)
BMI, body mass index; GCSE, General Certificate of Secondary Education;
IQR, interquartile range; MSM, men who have sex with men; MSW, men
who have sex with women; SD, standard deviation.
*v2 test.
#
Mann–Whitney U-test.
□
Fisher’s exact test.
9
Independent samples t-test.
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a median of 15 (IQR 8–20) vs. 10 (5–13) cigarettes per day for
current smokers, respectively (P < 0.001).
Past recreational drug use was more often reported in
those with HIV infection, with 60% indicating drug use
ever compared with 48% of HIV-negative participants
(P = 0.05). No significant differences were found in the
proportion of participants indicating any recreational
drug use in the past 3 months.
Spirometry, respiratory symptoms and health-related
quality of life
Spirometry was within normal limits in most people: 18
(11%) HIV-positive and seven (9%) HIV-negative partici-
pants had evidence of airflow obstruction (FEV1/
FVC < 0.7) (P = 0.55).
The MRC dyspnoea and SGRQ scores suggested a
higher prevalence of breathlessness and respiratory health
status impairment in PLWH (Table 4). SGRQ scores were
higher in the HIV-positive group for all domains, with
median SGRQ Total scores of 12 in the PLWH and 6 in
HIV-negative participants (P < 0.01). Breathlessness was
more common in the HIV-positive group, with 47% hav-
ing an MRC dyspnoea score ≥ 2 (on a scale of 1–5), sug-
gesting at least moderate breathlessness, compared with
25% of the HIV-negative participants (P = 0.001); 13% of
HIV-positive vs. 1% of HIV-negative participants had
MRC dyspnoea scores of ≥ 3 (P = 0.001).
There was no significant difference in general health-
related quality of life scores between the HIV-positive and
HIV-negative groups, with median EQ5D (UK) index val-
ues of 0.88 and 0.85 (P = 0.06) and median Visual Analo-
gue Scale scores of 78 and 72, respectively (P = 0.46).
Factors associated with respiratory health status
impairment in univariable analyses
In addition to HIV status, we explored other possible con-
tributors to impaired respiratory health in the whole
Table 2 Comparison of comorbidities and their management
between HIV-positive and HIV-negative participants
HIV-positive
(n = 197)
HIV-negative
(n = 93) P-value
Diagnosis of comorbid conditions (self-report), ever [n (%)]
Asthma 36 (18) 21 (23) 0.34□
COPD/emphysema 9 (5) 1 (1) 0.18□
Cancer (any) 9 (5) 3 (3) 0.76□
Heart disease 11 (6) 4 (4) 0.78□
Stroke 3 (1) 1 (1) 1□
Diabetes 10 (5) 6 (7) 0.59□
Currently receiving treatment
for depression [n (%)]
40 (20) 8 (9) 0.02*
Patient Health Questionnaire – 9
score [median (IQR)]
4 (1–8) 2 (0–6) 0.002#
Patient Health Questionnaire – 9
score ≥ 10 [n (%)]
39 (20) 13 (14) 0.254□
Self-reported history of immunization against [n (%)]
Influenza in past 12 months 138 (70) 27 (30) < 0.01□
Streptococcus pneumonia (ever) 50 (26) 6 (7) < 0.01□
Use of inhaled
medications (any) [n (%)]
24 (12) 15 (17) 0.30*
Undertakes physical activity
at least once per week [n (%)]
115 (59) 63 (71) 0.05*
History of acute respiratory illness
in past year [n (%)]
Sinusitis 23 (12) 7 (8) 0.41□
Bronchitis 6 (3) 3 (3) 1.0□
Chest infection 39 (20) 11 (12) 0.132□
Cold or flu serious enough
to miss work or stop
normal activities
54 (28) 19 (21) 0.307□
Pneumonia 3 (1.5) 0 0.55□
Any acute respiratory illness 93 (47) 30 (32) 0.02*
COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
□
Fisher’s exact test.
*v2 test.
#
Mann–Whitney U-test.
Table 3 Smoking and recreational drug use
HIV-positive
(n = 197)
HIV-negative
(n = 93) P-value
Smoking [n (%)]
Current smoker 60 (30) 31 (33) 0.81□
Ex-smoker 54 (27) 22 (24)
Never smoker 80 (41) 37 (40)
Not stated 3 (1.5) 3 (3)
Cigarettes smoked per day
(current smokers only)
[median (IQR)]
15 (8–20) 10 (5–13) < 0.01#
Most cigarettes smoked
per day in the past
[median (IQR)]
20 (15–30) 12.5 (7.5–20) 0.04#
Currently using electronic
cigarettes [n (%)]
20 (18) 8 (16) 0.83*
History of recreational drugs use, ever [n (%)]
Any 118 (61) 41 (48) 0.07□
Cannabis 98 (51) 35 (41) 0.15□
Cocaine (smoked) 23 (12) 3 (3) 0.03□
Cocaine (sniffed or
rubbed in gums)
71 (37) 21 (25) 0.05□
Ecstasy/Gamma-hydroxybutyrate/
ketamine/
crystal meth
72 (36) 13 (14) < 0.001□
Heroin (smoked) 13 (7) 1 (1) 0.07□
Heroin (injected) 7 (4) 1 (1) 0.44□
History of recreational drug use in last 3 months [n (%)]
Any 58 (30) 18 (20.7) 0.15□
Cannabis 39 (20) 14 (16.1) 0.51□
Cocaine (smoked) 3 (1) 0 0.55□
Cocaine (sniffed or
rubbed in gums)
13 (7) 8 (9) 0.47□
Ecstasy/Gamma-hydroxybutyrate/
ketamine/crystal meth
22 (11) 3 (3) 0.025□
Heroin (smoked) 3 (1) 0 0.55□
Heroin (injected) 0 0 –
IQR, interquartile range.
□
Fisher’s exact test.
#Mann–Whitney U-test.
*v2 test.
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study sample (Table S1). Higher SGRQ scores were associ-
ated with impaired lung function, with a median total
SGRQ score of 28.5 (IQR 7.2–41.9) in people with an
FEV1 < 80% predicted compared with 9.1 (IQR 4.4–17.4)
in those with an FEV1 in the normal range (P < 0.01).
Symptoms of depression were associated with impaired
self-reported respiratory health status: median SGRQ
Total scores were 26.5 in the 52 participants with PHQ-9
scores of ≥ 10, and 7.7 in the 238 participants with PHQ-
9 scores < 10.
Combining HIV-positive and HIV-negative groups, no
significant associations were found between gender, eth-
nicity, smoking status or recreational drug use and
impaired respiratory health status in univariable analyses.
An association between body mass index (BMI) and
SGRQ Total score was seen (with higher scores in those
with BMI < 20 or > 25), which approached statistical
significance (P = 0.07).
Associations between HIV-related parameters and
respiratory health
In analyses restricted to HIV-positive participants, nei-
ther current nor nadir CD4 count was significantly asso-
ciated with higher SGRQ Total score (although trends
were seen for higher scores being related to lower cur-
rent or nadir blood CD4 counts). No significant differ-
ence in median SGRQ Total score was identified in
those with and without an HIV load < 40 copies/mL
(Table 5). After adjustment for age in a log-scale linear
regression model, there was a trend towards higher
SGRQ Total scores in people with a longstanding HIV
diagnosis. A significant association was present between
higher SGRQ Total score and longer interval from HIV
diagnosis to starting ART.
Multivariable analysis of factors associated with
respiratory health status including all participants
To allow adjustment for potential confounding factors,
we constructed multivariable (log scale) linear regression
models including all participants, with log SGRQ as the
dependent variable. In addition to those factors chosen a
priori (smoking status, age and gender), PHQ-9 scores
and BMI were also included as they reached statistical
significance at the 5% level in univariable analysis.
After adjustment for these other factors, HIV infection
remained independently associated with an increased SGRQ
Total score, with a 54% higher SGRQ Total score compared
with HIV-negative individuals [adjusted fold-change 1.54;
95% confidence interval (CI) 1.14–2.09; P = 0.005]
(Table 6). Depression (PHQ-9 score ≥ 10) was also indepen-
dently associated with a higher SGRQ Total score (adjusted
fold-change 1.90; 95% CI 1.42–2.53; P < 0.001).
We found similar factors to be independently associ-
ated with an MRC dyspnoea score ≥ 2 in a multivariable
logistic regression model (Table S2). Here, the adjusted
odds ratio (aOR) for an MRC dyspnoea score of ≥ 2 was
2.84 (95% CI 1.35–6.00; P = 0.006) in HIV-positive com-
pared with HIV-negative participants. Independent associ-
ations were found with female gender (aOR 4.69; 95% CI
1.85–11.45; P = 0.001) and depression (aOR 6.30; 95% CI
2.75–14.46; P < 0.001).
Comparing HIV-positive participants with an
undetectable HIV viral load with HIV-negative
participants
As other studies have suggested that untreated HIV infec-
tion is associated with chronic respiratory impairment
[18, 19], a greater prevalence of respiratory symptoms
Table 4 Respiratory symptoms and health status
HIV-positive
(n = 197)
HIV-negative
(n = 93) P-value
FEV1
Mean (SD) (L) 3.49 (0.87)* 3.25 (0.76)* 0.56D
% predicted 93 91
FVC
Mean (SD) (L) 4.29 (1.05)* 3.95 (0.91)* 0.23a
% predicted 91 89
FEV1/FVC < 0.7 [n (%)] 18 (11)* 7 (9)* 0.50
□
MRC dyspnoea scale [n (%)]
1. Not troubled by
breathlessness except
on strenuous exercise
99 (53) 61 (75) 0.02□
2. Short of breath when
hurrying or walking up a
slight hill
62 (33) 1 (24)
3. Walk slower than
contemporaries on level ground
or have to stop for breath when
walking at your own pace
8 (4) 1 (1)
4. Stop for breath after walking
about 100 m or after a few
minutes on level ground
13 (7) 1 (0)
5. Too breathless to leave the
house, or breathless when
dressing/undressing
4 (2) 0 (0)
St George’s Respiratory Questionnaire [median (IQR)]
Symptoms 25 (7–48) 18 (0–29) < 0.01#
Activity 17 (6–36) 12 (0–19) < 0.01#
Impacts 5 (0–15) 0 (0–6) < 0.01#
Total 12 (6–25) 6 (2–14) < 0.01#
IQR, interquartile range; SD, standard deviation.
*157 (80%) HIV-positive and 74 (80%) HIV-negative participants had
acceptable spirometry results.
Dt-test; comparison of FEV % predicted.
at-test; comparison of FVC % predicted.
□
Fisher’s exact test.
#Mann–Whitney U-test.
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within the PLWH population as a whole might result
from increased symptoms only among HIV-positive
individuals not yet taking ART, or on ART without
virological suppression. We therefore undertook a sub-
group analysis comparing HIV-negative participants
with HIV-positive participants whose HIV viral load
was measured as being undetectable (< 40 copies/mL)
within 6 months of the study visit. Participants who
declined consent to access clinical records were
excluded from this analysis, leaving 157 HIV-positive
participants with documented virological suppression,
compared with the 93 HIV-negative participants. Those
with virological suppression had similar demographic
characteristics to the PLWH study population as a
whole (Table S3) and had a median CD4 count of 684
(IQR 473–839) cells/lL. The differences in respiratory
health scores between HIV-positive (HIV suppressed)
and HIV-negative groups were similar to those present
in the complete data set: median SGRQ Total scores
were 12 (IQR 6–25) and 6 (IQR 2–14), respectively
(P < 0.001); and seventy (47.3%) of the HIV-positive
group had MRC dyspnoea scores of ≥ 2 compared with
20 (24.7%) of the HIV-negative group (P = 0.001). In a
log-scale linear regression model (including the same
predictive factors as the whole-group analysis), HIV
status remained independently associated with a higher
SGRQ Total score, with a similar effect size to that in
the whole group (fold-change in SGRQ 1.53; 1.13–2.06;
P = 0.007).
Table 5 Associations between HIV-related factors and St George’s Respiratory Questionnaire (SGRQ) Total score
HIV-positive
participants [n (%)]
SGRQ Total
[median (IQR)]
Unadjusted fold-change
in SGRQ* (95% CI)
Age-adjusted fold-change
in SGRQ (95% CI)* P-value*
Current CD4 count (cells/lL)
0–350 19 (11) 20 (6–35) 1.53 (0.88–2.18) 1.57 (0.94–2.62) 0.109
350–500 30 (18) 16 (9–34) 1.39 (0.91–2.54) 1.40 (0.90–2.19)
≥ 500 119 (71) 11 (6–20) Reference
Viral load < 40 copies/mL at last clinic review
No 19 (11) 15 (5–67) 1.31 (0.78–2.19) 1.52 (0.89–2.57) 0.12
Yes 149 (89) 13 (6–25) Reference
Nadir CD4 count (cells/lL)
0–100 35 (21) 17 (7–43) 1.80 (0.98–3.32) 1.65 (0.88–1.74) 0.112
100–250 47 (28) 16 (8–33) 1.52 (0.85–2.73) 1.40 (0.76–2.55)
250–500 67 (40) 12 (6–17) 1.04 (0.60–1.81) 1.0 (0.57–3.09)
≥ 500 17 (10) 10.5 (4–14) Reference
Time since HIV diagnosis (years)
> 20 47 (27) 16 (8–37) 1.72 (1.14–2.61) 1.56 (1.01–2.43) 0.067
10–20 62 (36) 11 (6–25) 1.24 (0.85–1.83) 1.19 (0.80–1.76)
< 10 62 (36) 10 (4–20) Reference
Time between HIV diagnosis and ART (years)
> 10 33 (20) 21 (11–48) 1.90 (1.23–2.91) 1.79 (1.17–2.75) 0.004
5–10 43 (25) 9 (5–26) 1.00 (0.68–1.45) 0.95 (0.64–1.39)
< 5 93 (55) 12 (5–21) Reference
Duration of ART exposure
> 10 68 (49) 17 (7–37) 1.73 (1.13–2.64) 1.58 (1.0–2.49) 0.148
5–10 26 (19) 13 (7–24) 1.54 (0.87–2.70) 1.41 (0.78–2.52)
< 5 46 (33) 9 (4–21) Reference
ART, antiretroviral therapy; CI, confidence interval; IQR, interquartile range.
*Log-scale linear regression model.
Table 6 Associations with St George’s Respiratory Questionnaire
(SGRQ) Total score in multivariable log-scale linear regression
analysis
Adjusted fold-change
in SGRQ* (95% CI) P-value
HIV status
HIV positive 1.58 (1.18–2.12) 0.002
HIV negative Reference
Age (per 1 year older) 1.01 (1.01–1.02) 0.335
Gender
Female 1.37 (0.96–1.09) 0.083
Male Reference
Depression (PHQ-9)
≥ 10 2.77 (1.98–3.88) <0.001
< 10 Reference
Body mass index (kg/m2)
< 20 1.18 (0.68–1.74) 0.681
≥ 20 < 25 Reference
≥ 25 < 30 1.18 (0.85–1.37)
≥ 30 1.23 (0.8–1.42)
Smoking
Current smoker 1.23 (0.89–1.24) 0.408
Ex-smoker 1.01 (0.72–2.57)
Never smoker Reference
CI, confidence interval.
*Log-scale linear regression model.
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Sensitivity analysis
To further explore the possible effect of the difference in
age distribution between the HIV-positive and HIV-nega-
tive groups, we undertook a sensitivity analysis where we
examined only those aged ≤ 52 years (the 75th centile of
the HIV-negative participants). Using this restricted anal-
ysis (including 127 HIV-positive and 69 HIV-negative
participants), the age distributions were similar, with a
median age of 42 years in both groups. The previously
demonstrated differences remained, with median SGRQ
Total scores of 11.2 (IQR 6–20) in the PLWH and 6.2 (IQR
3–15) in the HIV-negative group (P = 0.01). MRC dysp-
noea scores were also higher, with 55 (46%) of the HIV-
positive and 16 (27%) of the HIV-negative participants
having a MRC dyspnoea score ≥ 2 (P = 0.01).
Discussion
We compared HIV-positive individuals to an HIV-nega-
tive group with similar exposures to risk factors such as
tobacco smoking. Our results suggest that HIV infection
remains associated with impaired respiratory health
despite virological suppression on ART. Although some
differences were present in the age and ethnicity compo-
sitions of our two groups, these could not explain the dif-
ferences in respiratory health status seen after adjustment
in multivariable analyses.
Breathlessness was common in HIV-positive partici-
pants, with 47% of PLWH reporting this to be present
and of at least moderate severity, compared with 25%
of the HIV-negative participants. Using the SGRQ respi-
ratory health questionnaire (which assesses not only res-
piratory symptoms but also the impacts on activity and
quality of life), we found a 6-point difference in the
median total score between HIV-positive and HIV-nega-
tive groups (a minimum clinically important difference
in SGRQ being around 4 points [20]), suggesting that
there is a meaningful impairment of the respiratory
health of PLWH. This difference was present despite the
prevalence of airflow obstruction in our HIV-positive
subjects (11%) being lower than that reported in other
HIV-positive populations (for instance 23% in Italy and
27% in the USA [8, 21]). Of note, there was also no dif-
ference in the prevalence of airflow obstruction in our
study between the HIV-positive and HIV-negative
groups.
To our knowledge, no other study has used patient-
reported outcomes to compare respiratory health status in
HIV-positive and HIV-negative populations. Two previous
reports used the SGRQ to evaluate respiratory health in
HIV-positive adults: Hirani et al. evaluated 98
consecutive HIV-positive individuals (84% male) attend-
ing HIV care services in Philadelphia, USA, and found a
mean SGRQ Total score of 7 [22]; in contrast, Leung
et al. reported a mean SGRQ Total score of 32 in 199
HIV-positive men attending care services in Vancouver,
Canada [9]. Our data therefore provide the first estimate
of the difference in respiratory health (as experienced by
individuals) between HIV-positive adults with optimized
access to ART and HIV-negative adults.
What might be contributing to these findings? Impair-
ment of lung function not measured by spirometry may
be present, which could result from a higher frequency of
respiratory infection prior to effective ART and lead to
long-term lung damage [23]: this could also result
from the direct effect of HIV in the lung [24]. Other
possibilities include cardiovascular disease or other non-
respiratory comorbidities which can lead to respiratory
symptoms. Depression was strongly associated with
impaired respiratory health in our population and this
may contribute to the burden of physical symptoms
(although it should be noted that the difference in
respiratory health status persisted after adjustment for
depression in our population). Persistent HIV-associated
immune dysregulation despite ART may also contribute –
an effect documented in the development of atherosclero-
sis [25]. This hypothesis is supported by Attia et al.’s
finding that levels of circulating CD14 are associated with
radiographic emphysema in HIV-positive individuals [26].
Prospective studies are needed to determine the relative
importance of these possible causes.
The strengths of our study include the presence of an
HIV-negative control group with similar exposures to
tobacco smoking and recreational drugs and the use of
well-validated measures of respiratory health status. Our
high response rate (72%) suggests that participants were
representative of the wider clinic population, who in turn
are similar to the UK HIV-infected population as a whole
[27].
Limitations include recruitment at a single study site
and the cross-sectional nature of the data collected,
meaning that temporality cannot be established. As peo-
ple were not randomly selected to participate, recruitment
bias is possible. Spirometry was our only objective mea-
sure of lung function, whereas several studies have sug-
gested that impairment of gas transfer is more common
than airflow obstruction in PLWH [28, 29]. The differ-
ences in age and ethnicity between groups could have
influenced our results; however, our findings persisted
after adjustment in multivariable analyses; and our sensi-
tivity analysis is reassuring in that the difference in age
distribution between HIV-positive and HIV-negative par-
ticipants appeared to have little impact on the results.
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Finally, we relied on self-reported HIV status in the HIV-
negative participants, so we cannot exclude the possibility
that HIV-positive or undiagnosed individuals were
included in this group. However, we believe that this is
unlikely to be a major issue as the prevalence of undiag-
nosed HIV infection in our sexual health clinics is low
(data not shown). If this did occur, it would have acted to
weaken the association between HIV infection and respi-
ratory health status impairment.
Interventions that can preserve the respiratory health
of people with chronic HIV infection are needed. The
earlier use of ART may reduce non-AIDS-related comor-
bidities, including respiratory illness – although, notwith-
standing a median duration of follow-up of only
2.8 years, this was not associated with differences in lung
function decline in the recent Strategic Timing of Antire-
troviral Treatment (START) trial [30]. However, the
impaired respiratory health of PLWH despite effective
virological suppression found in our study suggests that
more than ART alone is required to maintain the health
of this population. Reducing the effect of known risk fac-
tors such as tobacco is important, as many HIV-positive
populations have high rates of smoking [31, 32]. Thus,
the provision of appropriate smoking cessation services
should be a priority. However, why HIV infection is asso-
ciated with apparent worse respiratory health even in
never-smokers remains uncertain and requires further
investigation.
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